Lipocine (NASDAQ:LPCN) Rating Increased to Hold at Wall Street Zen

Lipocine (NASDAQ:LPCN) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other equities analysts have also recently issued reports on the stock. Weiss Ratings cut shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 18th. HC Wainwright reaffirmed a “neutral” rating on shares of Lipocine in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Lipocine presently has an average rating of “Hold” and a consensus target price of $15.00.

Lipocine Stock Performance

Shares of LPCN opened at $2.23 on Friday. The firm’s 50-day simple moving average is $2.31 and its 200 day simple moving average is $5.33. The firm has a market cap of $18.38 million, a P/E ratio of -1.19 and a beta of 0.44. Lipocine has a 52 week low of $1.81 and a 52 week high of $12.37.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.16 million. Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%. As a group, equities analysts forecast that Lipocine will post -1.91 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its stake in shares of Lipocine by 57.5% during the first quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after purchasing an additional 6,982 shares during the period. Ikarian Capital LLC acquired a new position in Lipocine in the fourth quarter valued at about $1,602,000. Boothbay Fund Management LLC acquired a new position in Lipocine in the fourth quarter valued at about $441,000. Jane Street Group LLC bought a new position in Lipocine during the fourth quarter worth about $85,000. Finally, Renaissance Technologies LLC boosted its holdings in Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after buying an additional 1,300 shares during the last quarter. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.